Adaptive Biotechnologies (ADPT) stock price is $23.95, down 0.29% on the day, as of Oct 19, 2026. It has a market cap of $3.82Bn, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.82 Bn
P/E-59.84
P/S12.40
Div. Yield0.00
Revenue Growth (1y) (Qtr)21.53
Add ratio to table…
About
Adaptive Biotechnologies Corporation decodes the adaptive immune system to transform disease diagnosis and treatment. The company specializes in immune medicine, leveraging proprietary technologies to sequence, map, and characterize T-cell and B-cell receptors at scale. Its platform combines next-generation sequencing, computational biology, and machine learning to generate clinical immunomics data, enabling the development of precision diagnostics and therapeutics for…
Adaptive Biotechnologies Corporation decodes the adaptive immune system to transform disease diagnosis and treatment. The company specializes in immune medicine, leveraging proprietary technologies to sequence, map, and characterize T-cell and B-cell receptors at scale. Its platform combines next-generation sequencing, computational biology, and machine learning to generate clinical immunomics data, enabling the development of precision diagnostics and therapeutics for cancer and autoimmune diseases.
The company generates revenue through clinical diagnostic testing and partnerships with biopharmaceutical firms. Its flagship product, clonoSEQ, is an FDA-authorized next-generation sequencing assay for minimal residual disease detection in lymphoid malignancies, sold directly to clinicians and used in drug development trials. The Immune Medicine business monetizes proprietary datasets, immune receptor sequencing services, and target discovery capabilities through licensing agreements and collaborations with pharmaceutical companies.
The company operates through the following segments:
MRD Business: This segment focuses on minimal residual disease detection in hematologic cancers using the clonoSEQ assay. It serves clinicians for patient monitoring and biopharmaceutical partners for drug development, with clonoSEQ being the first and only FDA-authorized test for multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The segment also offers laboratory-developed tests for other lymphoid cancers, including diffuse large B-cell lymphoma and mantle cell lymphoma.
Immune Medicine Business: This segment leverages the company’s immunosequencing platform to sequence, pair, and characterize T-cell and B-cell receptors. It provides immune receptor sequencing services, licenses proprietary datasets matching TCRs to antigens, and offers TCR-antigen prediction models and target discovery capabilities. The segment collaborates with pharmaceutical companies to accelerate therapeutic research in autoimmune diseases and oncology.
Adaptive Biotechnologies Corporation holds a leading position in immune medicine, distinguished by its proprietary immunosequencing platform and clinical immunomics database. Its clonoSEQ assay is the only FDA-authorized next-generation sequencing test for minimal residual disease in lymphoid malignancies, offering industry-leading sensitivity of one cancer cell per million. The company’s competitive advantages include a robust intellectual property portfolio, regulatory expertise, and a growing dataset of over 5 million TCR-antigen matches. Key competitors include companies developing flow cytometry-based MRD tests, circulating tumor DNA assays, and other immune profiling technologies, though none match Adaptive’s scale or clinical validation.
The company serves a diverse customer base, including hematologists, oncologists, and biopharmaceutical companies. Its clonoSEQ test is used in over 180 clinical trials conducted by more than 40 biopharmaceutical partners, including Pfizer. The Immune Medicine segment collaborates with pharmaceutical firms to advance drug discovery and development in autoimmune diseases and oncology. Additionally, the company’s diagnostic services are utilized by hospitals, cancer centers, and community clinics across the United States.
Sector:HealthcareSector rationaleThe company's primary revenue comes from clinical diagnostic testing (clonoSEQ) and providing immune receptor sequencing services for drug discovery to biopharmaceutical firms. These activities fall squarely within the Healthcare sector's industries of Diagnostic Equipment, Life Sciences Tools, and Healthcare Services.Industries:Diagnostic LabsDiagnostic LabsPrimaryThe company generates significant revenue through clinical diagnostic testing, specifically its FDA-authorized clonoSEQ assay used by clinicians, hospitals, and cancer centers for minimal residual disease detection in lymphoid malignancies.Contract ResearchContract ResearchSecondaryThe company provides immune receptor sequencing services and target discovery capabilities to biopharmaceutical partners to accelerate therapeutic research in oncology and autoimmune diseases.Classified using BQ-MICSCIK: 0001478320
Bull & bear
Investment Thesis
▲ Bull case
Adaptive Biotechnologies is demonstrating sustainable operational excellence that positions it for accelerated profitability in 2026 and beyond, with sequencing gross margin expanding eight percentage points year-over-year to 70% driven by NovaSeq X efficiencies and scale benefits, and management explicitly targeting 75% gross margin as a north star for the year, indicating significant further upside in contribution margin that could rapidly accelerate the path to company-wide adjusted EBITDA positivity as revenue continues to scale and fixed costs are absorbed, creating a powerful operating leverage effect that the market may be underestimating given the current revenue growth trajectory and expense discipline.
The company’s EMR integration strategy is evolving beyond simple connectivity into deep workflow optimization, with 150 community network practices now live on Epic and Flatiron platforms and strong pull-through rates of 72% for serial monitoring orders, signaling that the initial integration phase is maturing into a retention and expansion engine that could drive disproportionate growth in repeat testing frequency and community adoption, particularly as standardized protocols take hold in large networks, reducing friction for clinicians and increasing the lifetime value of each account beyond what is reflected in current volume guidance.
Adaptive’s biopharma business is building a self-reinforcing flywheel where pharma partnerships are not only generating near-term milestone revenue but also creating real-world evidence that expands clinical utility, as evidenced by the PERSEUS trial establishing sustained MRD negativity as a meaningful response metric in multiple myeloma, which directly supports broader adoption of clonoSEQ in clinical practice, and with 20 ongoing interventional studies using MRD for enrollment or therapy guidance, the data generated from these trials is likely to fuel future clinical demand independent of direct pharma spending, creating a durable competitive advantage that is not fully priced into the current guidance.
The Texas Medicaid policy inclusion, granting coverage of up to six clonoSEQ tests per year for eligible patients, represents a significant and underappreciated catalyst for community-based adoption, particularly as it addresses access barriers for vulnerable populations and aligns with the company’s success in growing community testing volumes 67% year-over-year to 35% of total MRD volume, suggesting that similar policy wins in other large states could unlock a multi-year expansion of the addressable market that is not yet reflected in current guidance ranges.
Immune medicine, while currently a drag on profitability, is advancing with tangible progress in its AI/ML platform, including over 6 million TCR-antigen pairs in the proprietary database and a validated digital model outperforming public benchmarks in predicting TCR-antigen binding, with the RA target discovery partnership with Pfizer having already received over 1,000 patient samples and on track to deliver a data package in 2026, indicating that the division is nearing inflection points where strategic partnerships or licensing deals could monetize the platform and transform it from a cost center into a potential revenue contributor, de-risking the long-term investment and providing optionality that is not captured in the current MRD-centric valuation.
Adaptive Biotechnologies is demonstrating sustainable operational excellence that positions it for accelerated profitability in 2026 and beyond, with sequencing gross margin expanding eight percentage points year-over-year to 70% driven by NovaSeq X efficiencies and scale benefits, and management explicitly targeting 75% gross margin as a north star for the year, indicating significant further upside in contribution margin that could rapidly accelerate the path to company-wide adjusted EBITDA positivity as revenue continues to scale and fixed costs are absorbed, creating a powerful operating leverage effect that the market may be underestimating given the current revenue growth trajectory and expense discipline.
The company’s EMR integration strategy is evolving beyond simple connectivity into deep workflow optimization, with 150 community network practices now live on Epic and Flatiron platforms and strong pull-through rates of 72% for serial monitoring orders, signaling that the initial integration phase is maturing into a retention and expansion engine that could drive disproportionate growth in repeat testing frequency and community adoption, particularly as standardized protocols take hold in large networks, reducing friction for clinicians and increasing the lifetime value of each account beyond what is reflected in current volume guidance.
Adaptive’s biopharma business is building a self-reinforcing flywheel where pharma partnerships are not only generating near-term milestone revenue but also creating real-world evidence that expands clinical utility, as evidenced by the PERSEUS trial establishing sustained MRD negativity as a meaningful response metric in multiple myeloma, which directly supports broader adoption of clonoSEQ in clinical practice, and with 20 ongoing interventional studies using MRD for enrollment or therapy guidance, the data generated from these trials is likely to fuel future clinical demand independent of direct pharma spending, creating a durable competitive advantage that is not fully priced into the current guidance.
The Texas Medicaid policy inclusion, granting coverage of up to six clonoSEQ tests per year for eligible patients, represents a significant and underappreciated catalyst for community-based adoption, particularly as it addresses access barriers for vulnerable populations and aligns with the company’s success in growing community testing volumes 67% year-over-year to 35% of total MRD volume, suggesting that similar policy wins in other large states could unlock a multi-year expansion of the addressable market that is not yet reflected in current guidance ranges.
Immune medicine, while currently a drag on profitability, is advancing with tangible progress in its AI/ML platform, including over 6 million TCR-antigen pairs in the proprietary database and a validated digital model outperforming public benchmarks in predicting TCR-antigen binding, with the RA target discovery partnership with Pfizer having already received over 1,000 patient samples and on track to deliver a data package in 2026, indicating that the division is nearing inflection points where strategic partnerships or licensing deals could monetize the platform and transform it from a cost center into a potential revenue contributor, de-risking the long-term investment and providing optionality that is not captured in the current MRD-centric valuation.
Adaptive Biotechnologies faces significant near-term profitability headwinds that are being downplayed by management, as the total company adjusted EBITDA loss of $2.5 million in Q1 FY26 includes a $10.4 million loss from the immune medicine segment, which declined 26% year-over-year to $3.8 million in revenue, and despite claims of disciplined capital allocation, the segment continues to consume substantial resources without a clear near-term path to profitability, raising concerns that the $15 million to $20 million annual cash burn guidance may be optimistic if immune medicine requires additional funding to sustain its AI/ML and partnership initiatives.
The company’s reliance on lump-sum pharma milestone revenue creates volatility and execution risk, as evidenced by the recognition of a $9 million primary endpoint milestone in Q1 FY26 from the CEPHIUS trial, with management explicitly stating they do not anticipate additional milestone revenue for the remainder of 2026, meaning that the raised full-year MRD revenue guidance of $260 million–$270 million implies only 25% year-over-year growth at the midpoint when excluding milestones, and any delay or failure in pharma trial readouts or milestone achievements could quickly reverse the recent revenue acceleration, leaving the business exposed to the inherent lumpiness of biopharma drug development cycles.
Reimbursement durability remains an unaddressed risk despite management’s assurances, as the company acknowledged it is actively working with MolDX to increase the number of tests per bundle under its episode structure, indicating current reimbursement terms may not be sustainable long-term, and while clonoSEQ is not currently subject to PAMA reporting requirements due to its billing structure not falling under the Clinical Laboratory Fee Schedule, any future regulatory shift that reclassifies its tests or alters MolDX policies could impose significant pricing pressure, particularly given that the vast majority of Medicare revenue is generated through the MolDX episode rate structure, and no contingency for such scenarios was detailed in the guidance or commentary.
The commercial organization is operating under a constrained hiring model with no significant expansion planned for 2026 despite strong volume growth and rising physician engagement, as the company maintains only 65 sales reps split between academic and community channels, which may limit its ability to capitalize on the momentum in community testing—where volumes grew 67% year-over-year and now represent 35% of total MRD volume—especially as competitors increase their field presence and the company relies on optimizing existing accounts rather than adding new capacity, creating a potential bottleneck in scaling adoption beyond current infrastructure.
Guidance updates appear reactive rather than forward-looking, as the full-year MRD revenue guidance was raised to $260 million–$270 million based solely on Q1 FY26 performance, with management citing stronger-than-expected clinical volume and continued momentum but providing no new data on leading indicators such as pipeline conversion rates, average sales cycle length, or EMR integration completion rates beyond the top 10 academic accounts, suggesting the upside may be limited to a one-quarter catch-up effect rather than a sustainable acceleration, and the lack of detail on what is driving the increased confidence in the 35%+ volume growth target raises questions about whether the guidance reflects genuine visibility or simply a response to a strong start.
Adaptive Biotechnologies faces significant near-term profitability headwinds that are being downplayed by management, as the total company adjusted EBITDA loss of $2.5 million in Q1 FY26 includes a $10.4 million loss from the immune medicine segment, which declined 26% year-over-year to $3.8 million in revenue, and despite claims of disciplined capital allocation, the segment continues to consume substantial resources without a clear near-term path to profitability, raising concerns that the $15 million to $20 million annual cash burn guidance may be optimistic if immune medicine requires additional funding to sustain its AI/ML and partnership initiatives.
The company’s reliance on lump-sum pharma milestone revenue creates volatility and execution risk, as evidenced by the recognition of a $9 million primary endpoint milestone in Q1 FY26 from the CEPHIUS trial, with management explicitly stating they do not anticipate additional milestone revenue for the remainder of 2026, meaning that the raised full-year MRD revenue guidance of $260 million–$270 million implies only 25% year-over-year growth at the midpoint when excluding milestones, and any delay or failure in pharma trial readouts or milestone achievements could quickly reverse the recent revenue acceleration, leaving the business exposed to the inherent lumpiness of biopharma drug development cycles.
Reimbursement durability remains an unaddressed risk despite management’s assurances, as the company acknowledged it is actively working with MolDX to increase the number of tests per bundle under its episode structure, indicating current reimbursement terms may not be sustainable long-term, and while clonoSEQ is not currently subject to PAMA reporting requirements due to its billing structure not falling under the Clinical Laboratory Fee Schedule, any future regulatory shift that reclassifies its tests or alters MolDX policies could impose significant pricing pressure, particularly given that the vast majority of Medicare revenue is generated through the MolDX episode rate structure, and no contingency for such scenarios was detailed in the guidance or commentary.
The commercial organization is operating under a constrained hiring model with no significant expansion planned for 2026 despite strong volume growth and rising physician engagement, as the company maintains only 65 sales reps split between academic and community channels, which may limit its ability to capitalize on the momentum in community testing—where volumes grew 67% year-over-year and now represent 35% of total MRD volume—especially as competitors increase their field presence and the company relies on optimizing existing accounts rather than adding new capacity, creating a potential bottleneck in scaling adoption beyond current infrastructure.
Guidance updates appear reactive rather than forward-looking, as the full-year MRD revenue guidance was raised to $260 million–$270 million based solely on Q1 FY26 performance, with management citing stronger-than-expected clinical volume and continued momentum but providing no new data on leading indicators such as pipeline conversion rates, average sales cycle length, or EMR integration completion rates beyond the top 10 academic accounts, suggesting the upside may be limited to a one-quarter catch-up effect rather than a sustainable acceleration, and the lack of detail on what is driving the increased confidence in the 35%+ volume growth target raises questions about whether the guidance reflects genuine visibility or simply a response to a strong start.